SCHEMBL2736727

SCHEMBL2736727

CCCCn1cc(-c2cc(Cl)ccc2Cl)cc(NC(=O)c2ccccc2C)c1=O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.56
KCNMA1 Q12791 1/20 0.47
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP2C9 P11712 1/20 0.43
LMNA P02545 2/20 0.42
S1PR4 O95977 1/20 0.42
MAPT P10636 1/20 0.41
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GRM4 Q14833 1/20 0.40
PNLIP P16233 1/20 0.40
PTGES O14684 1/20 0.40
DHODH Q02127 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736728 0.91 CNR2 (0.59) CNR2KCNMA1ALDH1A1HPGDMEN1
SCHEMBL2760181 0.84 CNR2 (0.64) CNR2HPGDMEN1KMT2ACYP2C9
SCHEMBL2760212 0.81 L3MBTL1 (0.47) ALDH1A1HPGDMEN1KMT2ACYP2C9
SCHEMBL2736717 0.81 ELANE (0.46) CNR2MEN1KMT2ASMN1; SMN2
SCHEMBL2736726 0.79 CNR2 (0.62) CNR2ALDH1A1HPGDLMNAPOLB
SCHEMBL2736885 0.77 CNR1 (0.52) CNR2ALDH1A1HPGDLMNAMAPT
SCHEMBL2736731 0.76 CNR2 (0.50) CNR2ALDH1A1HPGDMEN1KMT2A
SCHEMBL2736888 0.76 LMNA (0.57) CNR2ALDH1A1HPGDMEN1KMT2A
SCHEMBL13531340 0.73 CNR2 (0.78) CNR2ALDH1A1MEN1KMT2ALMNA
SCHEMBL2736889 0.72 PTGER4 (0.44) CNR2ALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20080312292-A1 Antipruritics YASUI KIYOSHI 2008-12-18 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed
US-20070027144-A1 Novel use of cannabinoid receptor agonist SHIONOGI & CO., LTD. (JP) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027144-A1 Novel use of cannabinoid receptor agonist CNR2, CNR1, OPRM1 CNR2 1/4885KCNMA1 2021/4885ALDH1A1 2784/4885
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CNR2 1/4885KCNMA1 1167/4885ALDH1A1 3078/4885
US-20080312292-A1 Antipruritics CNR1, CNR2, OPRL1 CNR2 2/4885KCNMA1 1842/4885ALDH1A1 3580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.